Leading the fight in pulmonary fibrosis

Pacific Therapeutics is a development stage Specialty Pharmaceutical Company focused on the identification and development of drug candidates to treat diseases of excessive scarring (fibrosis).

The lead product candidate PTL-202 is a combination of drugs that have been approved by the FDA for indications other than fibrosis. PTL-202 is being developed to treat the progressive lung scarring disease, Idiopathic pulmonary fibrosis a $2 billion market opportunity.

Pacific is executing a strategy that reduces the risk, time and cost of developing therapies for fibrosis by combining compounds with known safety and toxicity profiles while avoiding the risks associated with basic research.